Intelligent Bio Solutions (INBS) has secured a new US patent for the Intelligent Fingerprinting Drug Screening Cartridge, reinforcing the protection of the company’s drug screening technology.
The patent, numbered 12259385, is crucial for the company’s testing system, which detects drugs in fingerprint sweat utilising lateral flow technology.
Go deeper with GlobalData
According to the company, this patent is the sixth active one for INBS in the US.
It improves the medical technology company’s portfolio, which comprises patents for its cartridge housing, buffer clip design, and Sample Collection Cartridge.
The Intelligent Fingerprinting Drug Testing Solution claims to identify common drugs of abuse through sweat analysis.
It is a “non-invasive” solution that meets the growing demand in several industries to ensure employee safety.
With the submission of the Food and Drug Administration (FDA) 510(k) last December, INBS aims to enter the country’s market this year.
The company states the drug screening system will transform portable testing with wider applications in additional fields.
The system claims to screen for drugs such as cocaine, methamphetamine, cannabis, and opiates by gathering the sample and offering the outcomes in less than ten minutes.
INBS CEO and president Harry Simeonidis said: “The intellectual property landscape for lateral flow devices in the US is mature, making the grant of this patent a strong validation of our innovative technology.
“The US is a key market for us, and securing broad intellectual property protection strengthens our competitive position as we plan for entry into this multi-billion dollar market in 2025.”
In November 2024, the company completed a method comparison study of its Intelligent Fingerprinting Drug Screening System, confirming its usability, accuracy, specificity, and sensitivity.
